Documente Academic
Documente Profesional
Documente Cultură
Michael Lesch and William Nyhan provided the first detailed clinical description of LESCH-NYHAN disease in 1964. The enzymatic defect associated with Lesch-Nyhan disease, deficiency of the enzyme hypoxanthine-guanine phosphoribosyl transferase (HPRT), was discovered by Seegmiller and colleagues in 1967. The gene encoding the human enzyme was cloned and sequenced by Friedmann and colleagues in 1985. Lesch-Nyhan disease is a genetic disorder associated with 3 major clinical elements: overproduction of uric acid, neurologic disability, and behavioral problems.[2] The overproduction of uric acid is associated with hyperuricemia. If left untreated, it can produce nephrolithiasis with renal failure, gouty arthritis, and solid subcutaneous deposits known as tophi. The neurologic disability is dominated by dystonia but may include choreoathetosis, ballismus, spasticity, or hyperreflexia. The behavioral problems include intellectual disability (mental retardation) and aggressive and impulsive behaviors. Patients with the classic disease also develop persistent and severe self-injurious behavior. Etiology Lesch-Nyhan disease and its variants are caused by mutations in the HPRT gene on the X chromosome.The mutations are heterogeneous, with more than 600 different ones documented, including single base substitutions, deletions, insertions, or substitutions Mutations in the HPRT1 gene cause Lesch-Nyhan syndrome. The HPRT1 gene provides instructions for making an enzyme called hypoxanthine phosphoribosyltransferase 1. This enzyme is responsible for recycling purines, a type of building block of DNA and its chemical cousin RNA. Recycling purines ensures that cells have a plentiful supply of building blocks for the production of DNA and RNA. HPRT1 gene mutations that cause Lesch-Nyhan syndrome result in a severe shortage (deficiency) or complete absence of hypoxanthine phosphoribosyltransferase 1. When this enzyme is lacking, purines are broken down but not recycled, producing abnormally high levels of uric acid. For unknown reasons, a deficiency of hypoxanthine phosphoribosyltransferase 1 is associated with low levels of a chemical messenger in the brain called dopamine. Dopamine transmits messages that help the brain control physical movement and emotional behavior, and its shortage may play a role in the movement problems and other features of this disorder. However, it is unclear how a shortage of hypoxanthine phosphoribosyltransferase 1 causes the neurological and behavioral problems characteristic of LeschNyhan syndrome. Some people with HPRT1 gene mutations produce some functional enzyme. These individuals are said to have Lesch-Nyhan variant. The signs and symptoms of Lesch-Nyhan variant are often milder than those of Lesch-Nyhan syndrome and do not include self-injury. Symptoms The first symptom of Lesch-Nyhan syndrome may be orange-colored crystal-like deposits in the diaper. This may occur in children as young as three months. These deposits are caused by increased uric acid in the urine. Other symptoms include:
Irritability Nervous system impairment: 4 to 6 monthslack of muscle tone and inability to lift the head 6 monthsunusual arching of the back 9 monthsinability to crawl or stand 12 monthsinability to walk 12+ monthsspasms of the limbs and facial muscles Blood in the urine Pain and swelling of joints Difficulty swallowing Behavioral problems and self injuryoccurs in all cases
Allopurinolto control excessive levels of uric acid in the body Diazepam, haloperidol, or phenobarbitalto help reduce problem behaviors Baclofento reduce muscle spasms
Behavioral problems may also be managed with a combination of behavioral modification techniques and medication. S-adenosylmethionineA single 2006 report suggests that administration of sadenosylmethionine, a food supplement, may reduce self-mutilating behaviors in adults with this syndrome. This supplement, which is available in health food stores, is naturally synthesized by the human body and important for many bodily processes. Talk to your doctor before taking any supplements.
With treatment, the average life expectancy is early- to mid-20s. There may be an increased risk of sudden death due to respiratory causes. However, many patients live longer with good medical and psychological care. Diagnosis The doctor will ask about symptoms, behavior traits, and medical history. A physical exam will be done. Your bodily fluids may be tested. This can be done with blood tests.